The Korean journal of internal medicine

  • 제30권4호
  • /
  • Pages.515-520
  • /
  • 2015
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Drug utilization review of mupirocin ointment in a Korean university-affiliated hospital

  • Youn, Sung Hee (Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Lee, Seung Soon (Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Sukyeon (Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Lee, Jeong-a (Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Bum Joon (Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Jounghee (Department of Pharmacy, Hallym University Sacred Heart Hospital) ;
  • Han, Hye-kyung (Department of Pharmacy, Hallym University Sacred Heart Hospital) ;
  • Kim, Jae-Seok (Department of Laboratory Medicine, Hallym University Kangdong Sacred Heart Hospital)
  • 투고 : 2014.07.25
  • 심사 : 2014.10.10
  • 발행 : 2015.07.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Intranasal mupirocin and chlorhexidine bathing are candidate strategies to prevent healthcare-associated infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In Korea, intranasal mupirocin is not available, and mupirocin ointment, an over-the-counter drug, has been used indiscriminately. Furthermore, because it is covered by health insurance, mupirocin is easy to prescribe within hospitals. Methods: We performed a mupirocin drug utilization review (DUR) within Hallym University Sacred Heart Hospital. Annual use of mupirocin was investigated between 2003 and 2013, and monthly consumption of mupirocin was assessed during the final 2-year period. The DUR focused on August 2012, the period of highest use of mupirocin. Also, we investigated trends in mupirocin resistance in MRSA between 2011 and 2013. Results: Annual consumption of mupirocin increased from 3,529 tubes in 2003 to 6,475 tubes in 2013. During August 2012, 817 tubes were prescribed to 598 patients; of these, 84.9% were prescribed to outpatients, and 77.6% at the dermatology department. The most common indication was prevention of skin infections (84.9%), and the ointment was combined with systemic antibiotics in 62.9% of cases. The average duration of systemic antibiotic administration was about 7.8 days. The rate of low-level mupirocin resistance in MRSA increased from 8.0% to 22.0%, and that of high-level mupirocin resistance increased from about 4.0% to about 7.5%. Conclusions: Inappropriate use of mupirocin is prevalent. Considering the increase in resistance and the future application of intranasal mupirocin, prophylactic use of mupirocin in dermatology departments should be reconsidered.

키워드

참고문헌

  1. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:1155-1161. https://doi.org/10.1086/520102
  2. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013;368:2255-2265. https://doi.org/10.1056/NEJMoa1207290
  3. Talon D, Marion C, Thouverez M, Bertrand X. Mupirocin resistance is not an inevitable consequence of mupirocin use. J Hosp Infect 2011;79:366-367. https://doi.org/10.1016/j.jhin.2011.08.009
  4. Walker ES, Levy F, Shorman M, David G, Abdalla J, Sarubbi FA. A decline in mupirocin resistance in methicillin- resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004;42:2792-2795. https://doi.org/10.1128/JCM.42.6.2792-2795.2004
  5. Hetem DJ, Bonten MJ. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect 2013;85:249-256. https://doi.org/10.1016/j.jhin.2013.09.006
  6. Lee AS, Macedo-Vinas M, Francois P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011;52:1422-1430. https://doi.org/10.1093/cid/cir233
  7. Lee H, Lim H, Bae IK, et al. Coexistence of mupirocin and antiseptic resistance in methicillin-resistant Staphylococcus aureus isolates from Korea. Diagn Microbiol Infect Dis 2013;75:308-312. https://doi.org/10.1016/j.diagmicrobio.2012.11.025
  8. Yun HJ, Lee SW, Yoon GM, et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003;51:619-623. https://doi.org/10.1093/jac/dkg140
  9. Yang JA, Park DW, Sohn JW, Yang IS, Kim KH, Kim MJ. Molecular analysis of isoleucyl-tRNA synthetase mutations in clinical isolates of methicillin-resistant Staphylococcus aureus with low-level mupirocin resistance. J Korean Med Sci 2006;21:827-832. https://doi.org/10.3346/jkms.2006.21.5.827
  10. Lee K, Lee HS, Jang SJ, et al. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J Korean Med Sci 2001;16:262-270. https://doi.org/10.3346/jkms.2001.16.3.262
  11. Kim HB, Jang HC, Nam HJ, et al. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob Agents Chemother 2004;48:1124-1127. https://doi.org/10.1128/AAC.48.4.1124-1127.2004
  12. Lee H, Jung D, Yeom JS, et al. Evaluation of ceftriaxone utilization at multicenter study. Korean J Intern Med 2009;24:374-380. https://doi.org/10.3904/kjim.2009.24.4.374
  13. Caffrey AR, Quilliam BJ, LaPlante KL. Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus. J Hosp Infect 2010;76:206-210. https://doi.org/10.1016/j.jhin.2010.06.023
  14. Lee AS, Macedo-Vinas M, Francois P, et al. Trends in mupirocin resistance in meticillin-resistant Staphylococcus aureus and mupirocin consumption at a tertiary care hospital. J Hosp Infect 2011;77:360-362. https://doi.org/10.1016/j.jhin.2010.11.002

피인용 문헌

  1. The Effects after Implementing a Drug Utilization Review System on Contraindicated Drug use: A Systematic Review vol.29, pp.1, 2019, https://doi.org/10.24304/kjcp.2019.29.1.9